Top 11 Plasma Fractionation Companies | Global Growth Insights

Introduction

Plasma Fractionation market is projected to reach US$ 47210 million by 2030 from an estimated US$ 30420 million in 2024, at a CAGR of 7.6% during 2024 and 2030

Plasma fractionation plays a critical role in modern healthcare, enabling the extraction and purification of essential proteins from blood plasma for therapeutic use. These proteins are used to treat a wide range of medical conditions, including immunodeficiency disorders, bleeding disorders, and autoimmune diseases. The global plasma fractionation market has seen substantial growth in recent years, driven by increasing demand for plasma-derived therapies, advancements in biotechnology, and a growing number of plasma collection centers worldwide. This article provides an in-depth analysis of the plasma fractionation industry, highlighting key players and trends shaping the market.

What is Plasma Fractionation?

Plasma fractionation is a process used to separate and purify plasma proteins, such as albumin, immunoglobulins, and clotting factors, for therapeutic use. Plasma, the liquid portion of blood, contains over 120 different proteins, each of which plays a vital role in various physiological functions. Fractionation involves using techniques like centrifugation, filtration, and precipitation to isolate these proteins. The demand for plasma-derived therapies has surged in recent years due to the growing prevalence of chronic diseases and the need for life-saving treatments.

Historical Perspective of Plasma Fractionation

Plasma fractionation dates back to the 1940s when it was developed during World War II to provide albumin for soldiers suffering from shock and burns. Over the decades, the process has evolved significantly, with the development of new technologies for protein separation and purification. The industry saw rapid growth in the 1980s with the introduction of therapies for hemophilia and other blood-related disorders. Today, plasma fractionation is a cornerstone of the pharmaceutical industry, with significant advancements in the production of safer, more effective therapies.

Market Dynamics and Growth Drivers

The global plasma fractionation market is poised for continued growth, with key drivers including:

• Rising Prevalence of Chronic Diseases: Conditions such as hemophilia, primary immunodeficiency disorders, and autoimmune diseases are driving the demand for plasma-derived therapies.
• Technological Advancements: New fractionation techniques and bioprocessing technologies are improving the efficiency and yield of plasma protein production.
• Increased Plasma Collection: The expansion of plasma donation centers and increased awareness about plasma donation are boosting plasma supply, which is essential for meeting growing therapeutic demand.
• Aging Population: The global rise in aging populations is contributing to the increased demand for therapies derived from plasma proteins, as older individuals are more susceptible to conditions requiring these treatments.

Global Growth Insights unveils the top global Plasma Fractionation Companies:

11. Takeda Pharmaceutical Company Limited

• Headquarters: Tokyo, Japan
• CAGR: ~6.5% (2023-2027)
• Revenue (2023): $34.6 billion

Takeda is a global leader in the plasma fractionation market, particularly after its acquisition of Shire in 2019, which gave it a strong foothold in rare diseases and plasma-derived therapies. The company is renowned for its immunoglobulin products, which are used to treat conditions such as primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy (CIDP). Takeda continues to invest in plasma collection and fractionation facilities worldwide, with a focus on expanding its reach in the immunology and hematology sectors.

10. CSL (CSL Behring)

• Headquarters: Melbourne, Australia
• CAGR: ~7.2% (2023-2027)
• Revenue (2023): $13.4 billion

CSL Behring, a subsidiary of CSL, is one of the largest plasma fractionation companies globally. It specializes in the development and manufacturing of plasma-derived and recombinant therapies. CSL Behring’s portfolio includes products used to treat bleeding disorders, immunodeficiency, and hereditary angioedema. The company has invested heavily in expanding its plasma collection centers, particularly in the U.S. and Europe, and continues to lead in innovation with a focus on new therapeutic areas, including gene therapy.

9. Grifols

• Headquarters: Barcelona, Spain
• CAGR: ~6.8% (2023-2027)
• Revenue (2023): €5.4 billion

Grifols is a key player in the plasma fractionation market, with a long history of producing plasma-derived therapies. The company operates one of the largest networks of plasma donation centers globally and is known for its leadership in immunoglobulins and albumin products. Grifols has also made significant strides in the development of treatments for neurodegenerative diseases and continues to expand its plasma collection infrastructure to meet growing demand for plasma-derived therapies.

8. Octapharma

• Headquarters: Lachen, Switzerland
• CAGR: ~6.3% (2023-2027)
• Revenue (2023): €2.5 billion

Octapharma is one of the largest privately-owned plasma fractionation companies globally. It focuses on the development of human proteins for use in pharmaceuticals, specializing in immunotherapy, hematology, and critical care. The company has a strong presence in Europe and has been expanding into new markets through partnerships and acquisitions. Octapharma is known for its high-quality plasma-derived immunoglobulins and clotting factors used to treat rare and chronic diseases.

7. Kedrion Biopharma

• Headquarters: Castelvecchio Pascoli, Italy
• CAGR: ~5.7% (2023-2027)
• Revenue (2023): €1.1 billion

Kedrion Biopharma focuses on the development and production of plasma-derived products for the treatment of rare and life-threatening diseases. The company is particularly known for its leadership in the production of hyperimmune globulins, used to treat various infectious diseases. Kedrion has a strong presence in Europe, the U.S., and emerging markets, with a focus on expanding its plasma collection network and enhancing its production capabilities to meet growing global demand.

6. LFB Group

• Headquarters: Les Ulis, France
• CAGR: ~5.4% (2023-2027)
• Revenue (2023): €900 million

LFB Group is a French biopharmaceutical company specializing in plasma-derived medicines and recombinant proteins for treating rare diseases. The company’s products are used in hematology, immunology, and intensive care settings. LFB Group is actively involved in research and development, with a strong focus on innovative plasma-derived therapies. It continues to expand its presence in Europe and other regions, driven by demand for therapies in rare disease treatment.

5. Biotest

• Headquarters: Dreieich, Germany
• CAGR: ~5.9% (2023-2027)
• Revenue (2023): €640 million

Biotest is a Germany-based global provider of plasma-derived products and biotherapeutic drugs. The company is recognized for its extensive product portfolio in immunology, hematology, and intensive care medicine. Biotest has been investing in the expansion of its production facilities, particularly in Europe and the U.S., to increase its capacity to manufacture plasma-derived therapies. The company’s focus on innovation has led to the development of new treatments for conditions such as immune disorders and coagulation deficiencies.

4. Bio Products Laboratory (BPL)

• Headquarters: Elstree, United Kingdom
• CAGR: ~5.3% (2023-2027)
• Revenue (2023): £450 million

Bio Products Laboratory (BPL) is a UK-based company that specializes in the production of plasma-derived therapies for use in immunology, hematology, and critical care. BPL has a strong focus on the development of products for the treatment of bleeding disorders, primary immunodeficiencies, and other rare diseases. The company has been expanding its plasma collection capabilities and continues to invest in R&D to develop new plasma-derived treatments for underserved therapeutic areas.

3. China Biologic Products Holdings, Inc. (CBPO)

• Headquarters: Beijing, China
• CAGR: ~6.9% (2023-2027)
• Revenue (2023): $700 million

China Biologic Products Holdings, Inc. (CBPO) is one of the largest plasma-derived product manufacturers in China. The company’s product portfolio includes human albumin, immunoglobulin, and clotting factors. CBPO has a significant presence in China and is expanding its operations internationally. The company’s growth is driven by the increasing demand for plasma-derived therapies in China, fueled by rising healthcare spending and a growing prevalence of chronic diseases.

2. RAAS (Shanghai RAAS Blood Products Co., Ltd.)

• Headquarters: Shanghai, China
• CAGR: ~7.1% (2023-2027)
• Revenue (2023): ¥4.6 billion

Shanghai RAAS is a leading Chinese plasma fractionation company, specializing in the production of blood products for the treatment of bleeding disorders and immune deficiencies. The company has a strong presence in China and has been expanding its international reach through partnerships and acquisitions. Shanghai RAAS has invested heavily in research and development to enhance its production capabilities and develop new therapies for rare and chronic diseases.

1. Hualan Biological Engineering Inc.

• Headquarters: Xinxiang, China
• CAGR: ~6.5% (2023-2027)
• Revenue (2023): ¥5.3 billion

Hualan Bio is a major player in China’s plasma fractionation industry, producing a wide range of plasma-derived products, including immunoglobulins, albumin, and coagulation factors. The company has a strong domestic presence and is expanding into international markets. Hualan Bio’s growth is driven by its extensive plasma collection network and its focus on innovation in plasma-derived therapies. The company continues to invest in expanding its production capacity to meet growing demand for its products.

Conclusion: The Future of Plasma Fractionation

The global plasma fractionation market is poised for sustained growth, driven by rising demand for plasma-derived therapies, advancements in fractionation technologies, and the expansion of plasma collection centers worldwide. Key players like Takeda, CSL Behring, Grifols, and Octapharma are leading the charge, leveraging their expertise and extensive infrastructure to meet growing global healthcare needs. The future of plasma fractionation will be shaped by innovations in bioprocessing, increasing awareness of plasma donation, and the development of new treatments for rare and chronic diseases.

As the market evolves, companies will need to focus on expanding their plasma collection networks, enhancing production capabilities, and investing in R&D to develop next-generation plasma-derived therapies. The demand for safer, more effective treatments will continue to grow, making plasma fractionation an indispensable part of modern healthcare.